El Grupo Menarini presenta en SABCS 2023 nuevos datos de supervivencia libre de progresión del estudio clínico EMERALD de ORSERDU® (elacestrant) en subgrupos clínicamente relevantes de pacientes con cáncer de mama metastásico (CMM) ER+, HER2- con mutaciones en ESR1 • Este nuevo análisis…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.